Physician profile
Jack E Giddings
NPI 1083781967
$4,089.50
in general payments reported to CMS, 2019-2025
38 companies · $65.64 in 2025
The $65.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $619 · 2021: $624 · 2022: $270 · 2023: $1,017 · 2024: $664 · 2025: $65.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $617.14 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $555.54 | 2019-2024 | Farxiga, Breztri, Flumist Quadrivalent |
| Novo Nordisk INC | $417.70 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.68 | 2020-2024 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $239.68 | 2019-2025 | |
| Abbott Laboratories | $232.60 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $231.04 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $130.30 | 2019-2023 | |
| Amarin Pharma, INC. | $119.43 | 2019 | |
| Exactech, INC. | $108.69 | 2019 | |
| Lilly USA, LLC | $103.90 | 2019-2024 | Mounjaro, Jardiance |
| Stryker Corporation | $103.03 | 2019 | |
| Intuitive Surgical, INC. | $85.90 | 2023 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $81.61 | 2020-2021 | |
| Inspire Medical Systems, INC. | $78.97 | 2024 | Inspire |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.99 | 2019-2020 | |
| Exact Sciences Corporation | $64.43 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $63.75 | 2024 | Repatha |
| Janssen Pharmaceuticals, INC | $52.41 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $44.45 | 2021 | |
| Medtronic, INC. | $38.92 | 2022 | |
| Abbvie INC. | $37.18 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.05 | 2020-2021 | |
| Hologic Sales and Service, LLC | $30.57 | 2019-2021 | |
| Daiichi Sankyo INC. | $30.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.58 | 2024 | Xifaxan |
| Eisai INC. | $21.46 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.85 | 2021 | |
| Ibsa Pharma INC. | $15.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.47 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2022 | |
| Ethicon US, LLC | $13.98 | 2020 | |
| Dermira, INC. | $13.86 | 2020 | |
| Mannkind Corporation | $13.21 | 2020 | |
| Exeltis, USA INC. | $11.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.08 | 2020 | |
| Cvrx, INC. | $6.34 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Giddings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.